Dutasteride for the Treatment of Benign Prostatic Hyperplasia

Dutasteride was found to be an effective, safe, and well-tolerated treatment for symptomatic benign prostatic hyperplasia (BPH), either as monotherapy or in combination with an α-blocker. It improved symptoms, reduced the risk of acute urinary retention, and decreased the need for BPH-related surgery. A new prostate-specific antigen baseline should be established after 6 months of therapy for clinical decision making. However, the relationship between dutasteride and high-grade prostate cancer remained unclear, and it was not approved for prostate cancer chemoprevention.